Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535806 · ClinicalTrials.gov registry record · Phase 2
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
A Phase 2 study, sponsored by Children's Mercy Hospital Kansas City.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02535806 is a Phase 2 study that was terminated before completion, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 2 participants.
The verdict
NCT02535806, a Phase 2 study, was terminated before completion, sponsored by Children's Mercy Hospital Kansas City.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a phase II study designed to investigate the combination of bortezomib with the mitoxantrone reinduction regimen used in the ALL R3 trial. The study will enroll patients with high risk ALL relapse including early bone marrow relapse and second or greater relapse of any kind. Patients with relapsed LL will also be eligible. Bone marrow evaluation will be performed after blood counts recover to assess the rate of CR (\<5% bone marrow blasts) and MRD status in children following this regimen. Further treatment with or without HSCT will be at the discretion of the primary physician.
Interventions
- DRUG Dexamethasone
- DRUG Mitoxantrone
- DRUG Methotrexate
- DRUG Velcade
- DRUG Methotrexate / Hydrocortisone / Cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02535806
The ClinicalTrials.gov registry entry for NCT02535806 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT02535806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02535806 about?
NCT02535806 is a clinical study titled "Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults". This is a phase II study designed to investigate the combination of bortezomib with the mitoxantrone reinduction regimen used in the ALL R3 trial. The study will enroll patients with high risk ALL relapse including early bone marrow relapse and second or greater relapse of any kind. Patients with re...
What is the current status of trial NCT02535806?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-07. Estimated completion is 2017-05-25.
What interventions are being tested in trial NCT02535806?
The interventions under investigation include: Dexamethasone (DRUG), Mitoxantrone (DRUG), Methotrexate (DRUG), Velcade (DRUG), Methotrexate / Hydrocortisone / Cytarabine (DRUG).
Who is sponsoring clinical trial NCT02535806?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.